Key facts
- InGel Therapeutics’s last known valuation is $17.0M (Jul 2024).
- It has raised $10.8M across 1 recorded rounds; the latest was Seed Round ($350K) in Jul 2022.
- Notable investors include Alumni Ventures, Service Provider Capital, Calm Ventures, Endless Frontier Labs, Harvard Innovation Launch Lab — 16 tracked in total.
- InGel Therapeutics has filed 1 Form D with the SEC, most recently Aug 2022 ($350K sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for InGel Therapeutics
Funding rounds
1 roundsAbout InGel Therapeutics
Developer of engineered cell therapy designed to target neuroprotective pathways to treat retinal degeneration. The company utilizes stem cells and their secretome for neuroprotection for blinding diseases like retinitis pigmentosa and macular degeneration through biodegradable polymers to isolate proteins of neuroprotective significance first in vitro and later in vivo, enabling healthcare professionals to treat the retinal degeneration of patients.
- Sector
- Healthcare
- HQ
- Allston, MA, United States
- Founded
- 2022
- Employees
- 8
- Website
- ingeltx.com/
- Ownership
- Privately Held (backing)
InGel Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InGel Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InGel Therapeutics in its N-PORT filings yet. We sweep new filings monthly.